|
MX3864E
(es)
*
|
1975-05-27 |
1981-08-26 |
Syntex Corp |
Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona
|
|
US4933168A
(en)
*
|
1975-05-27 |
1990-06-12 |
Syntex Pharmaceuticals International Limited |
Stable, crystalline flunisolide
|
|
GB1571629A
(en)
*
|
1977-11-30 |
1980-07-16 |
Fisons Ltd |
Pharmaceutical compositions containing beclomethasone dipropionate
|
|
IT1121513B
(it)
*
|
1979-05-28 |
1986-04-02 |
Chiesi Farma Spa |
Processo per la conversione di umo steroide antiinfiammatorio in una forma suscettibile di essere somministarta come aerosol
|
|
ATE3774T1
(de)
*
|
1980-05-02 |
1983-06-15 |
Schering Corporation |
Beclomethason-ester-solvate, verfahren zu ihrer herstellung und herstellung einer formulierung.
|
|
FI63672C
(fi)
*
|
1980-05-19 |
1983-08-10 |
Orion Yhtymae Oy |
Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan
|
|
KR890000664B1
(ko)
*
|
1981-10-19 |
1989-03-22 |
바리 안소니 뉴우샘 |
미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
|
|
GB8432063D0
(en)
*
|
1984-12-19 |
1985-01-30 |
Riker Laboratories Inc |
Physically modified steroids
|
|
US5962490A
(en)
*
|
1987-09-25 |
1999-10-05 |
Texas Biotechnology Corporation |
Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US5562608A
(en)
*
|
1989-08-28 |
1996-10-08 |
Biopulmonics, Inc. |
Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation
|
|
US5736509A
(en)
*
|
1990-12-14 |
1998-04-07 |
Texas Biotechnology Corporation |
Cyclic peptide surface feature mimics of endothelin
|
|
US5744123A
(en)
*
|
1991-12-12 |
1998-04-28 |
Glaxo Group Limited |
Aerosol formulations containing P134a and particulate medicaments
|
|
US5916540A
(en)
|
1994-10-24 |
1999-06-29 |
Glaxo Group Limited |
Aerosol formulations containing P134A and/or P227 and particulate medicament
|
|
US5653962A
(en)
*
|
1991-12-12 |
1997-08-05 |
Glaxo Group Limited |
Aerosol formulations containing P134a and particulate medicaments
|
|
US5658549A
(en)
*
|
1991-12-12 |
1997-08-19 |
Glaxo Group Limited |
Aerosol formulations containing propellant 134a and fluticasone propionate
|
|
IL104068A
(en)
|
1991-12-12 |
1998-10-30 |
Glaxo Group Ltd |
Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
|
|
CA2125666C
(en)
|
1991-12-12 |
2002-07-16 |
Rachel Ann Akehurst |
Medicaments
|
|
US5674471A
(en)
*
|
1991-12-12 |
1997-10-07 |
Glaxo Group Limited |
Aerosol formulations containing P134a and salbutamol
|
|
US5736124A
(en)
*
|
1991-12-12 |
1998-04-07 |
Glaxo Group Limited |
Aerosol formulations containing P134a and particulate medicament
|
|
US7101534B1
(en)
|
1991-12-18 |
2006-09-05 |
3M Innovative Properties Company |
Suspension aerosol formulations
|
|
US5301664A
(en)
*
|
1992-03-06 |
1994-04-12 |
Sievers Robert E |
Methods and apparatus for drug delivery using supercritical solutions
|
|
ES2177544T3
(es)
*
|
1992-06-12 |
2002-12-16 |
Teijin Ltd |
Polvo ultrafinno para inhalar y metodo para su preparacion.
|
|
MX9304585A
(es)
|
1992-07-31 |
1994-03-31 |
Glaxo Group Ltd |
Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
|
|
WO1994022427A1
(en)
*
|
1993-04-01 |
1994-10-13 |
Amgen Inc. |
Method for preparing drugs to treat dermal disorders
|
|
US6613804B2
(en)
|
1993-05-20 |
2003-09-02 |
Encysive Pharmaceuticals, Inc. |
Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US6030991A
(en)
*
|
1993-05-20 |
2000-02-29 |
Texas Biotechnology Corp. |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
|
US6342610B2
(en)
|
1993-05-20 |
2002-01-29 |
Texas Biotechnology Corp. |
N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US6376523B1
(en)
|
1994-05-20 |
2002-04-23 |
Texas Biotechnology Corporation |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
|
US6541498B2
(en)
|
1993-05-20 |
2003-04-01 |
Texas Biotechnology |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
|
EP0774956A1
(en)
*
|
1994-08-09 |
1997-05-28 |
Schering Corporation |
PROCESS FOR PREPARING BECLOMETHASONE DIPROPIONATE FREON$m(3) CLATHRATE
|
|
US5980949A
(en)
*
|
1994-10-03 |
1999-11-09 |
Astra Aktiebolag |
Formulation for inhalation
|
|
US5983956A
(en)
*
|
1994-10-03 |
1999-11-16 |
Astra Aktiebolag |
Formulation for inhalation
|
|
US5804560A
(en)
*
|
1995-01-06 |
1998-09-08 |
Sibia Neurosciences, Inc. |
Peptide and peptide analog protease inhibitors
|
|
US6017887A
(en)
*
|
1995-01-06 |
2000-01-25 |
Sibia Neurosciences, Inc. |
Peptide, peptide analog and amino acid analog protease inhibitors
|
|
US5646130A
(en)
*
|
1995-06-30 |
1997-07-08 |
Ocean University Of Oingdao |
Low molecular weight sulfated polysaccharides and uses thereof
|
|
US5977117A
(en)
*
|
1996-01-05 |
1999-11-02 |
Texas Biotechnology Corporation |
Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
|
|
US5700487A
(en)
*
|
1996-03-04 |
1997-12-23 |
The Ohio State University |
Treatment of pulmonary inflammation
|
|
US5958905A
(en)
|
1996-03-26 |
1999-09-28 |
Texas Biotechnology Corporation |
Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
|
|
US5804585A
(en)
*
|
1996-04-15 |
1998-09-08 |
Texas Biotechnology Corporation |
Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
|
|
AU736301B2
(en)
*
|
1996-05-01 |
2001-07-26 |
Imarx Therapeutics, Inc. |
Methods for delivering compounds into a cell
|
|
US6416960B1
(en)
|
1996-08-08 |
2002-07-09 |
Prolume, Ltd. |
Detection and visualization of neoplastic tissues and other tissues
|
|
US6380222B2
(en)
|
1996-10-11 |
2002-04-30 |
Astrazeneca Ab |
Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps
|
|
SE9603725D0
(sv)
*
|
1996-10-11 |
1996-10-11 |
Astra Ab |
New teatment
|
|
WO1998026277A2
(en)
|
1996-12-12 |
1998-06-18 |
Prolume, Ltd. |
Apparatus and method for detecting and identifying infectious agents
|
|
SE9700133D0
(sv)
*
|
1997-01-20 |
1997-01-20 |
Astra Ab |
New formulation
|
|
SE9700135D0
(sv)
*
|
1997-01-20 |
1997-01-20 |
Astra Ab |
New formulation
|
|
HU227183B1
(en)
|
1997-04-28 |
2010-09-28 |
Encysive Pharmaceuticals Inc |
Sulfonamide derivatives and pharmaceutical compositions containing them for the treatment of endothelin-mediated disorders
|
|
US5783705A
(en)
|
1997-04-28 |
1998-07-21 |
Texas Biotechnology Corporation |
Process of preparing alkali metal salys of hydrophobic sulfonamides
|
|
US6342611B1
(en)
*
|
1997-10-10 |
2002-01-29 |
Cytovia, Inc. |
Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
|
|
US6362009B1
(en)
|
1997-11-21 |
2002-03-26 |
Merck & Co., Inc. |
Solid phase synthesis of heterocycles
|
|
EP1054694A2
(en)
|
1998-02-13 |
2000-11-29 |
Selective Genetics, Inc. |
Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby
|
|
EP1925320A3
(en)
|
1998-03-27 |
2008-09-03 |
Prolume, Ltd. |
Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics
|
|
ATE276754T1
(de)
*
|
1998-07-21 |
2004-10-15 |
Cytovia Inc |
Neue fluoreszensfarbstoffe und ihre anwendung in fluoreszensnachweisverfahren ganzer zellen für kaspasen, peptidasen, proteasen und andere enzyme sowie deren verwendung
|
|
US6667299B1
(en)
*
|
2000-03-16 |
2003-12-23 |
Hollis-Eden Pharmaceuticals, Inc. |
Pharmaceutical compositions and treatment methods
|
|
US6638977B1
(en)
|
1999-11-19 |
2003-10-28 |
Corvas International, Inc. |
Plasminogen activator inhibitor antagonists
|
|
WO2001036351A2
(en)
|
1999-11-19 |
2001-05-25 |
Corvas International, Inc. |
Plasminogen activator inhibitor antagonists related applications
|
|
US7897140B2
(en)
|
1999-12-23 |
2011-03-01 |
Health Research, Inc. |
Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
|
|
SK9532002A3
(en)
|
1999-12-31 |
2003-06-03 |
Texas Biotechnology Corp |
Sulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US7109315B2
(en)
|
2000-03-15 |
2006-09-19 |
Bruce J. Bryan |
Renilla reniformis fluorescent proteins, nucleic acids encoding the fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
|
|
US6544497B2
(en)
|
2001-02-15 |
2003-04-08 |
Aeropharm Technology Incorporated |
Modulated release particles for aerosol delivery
|
|
US6596262B2
(en)
|
2001-02-15 |
2003-07-22 |
Aeropharm Technology Incorporated |
Modulated release particles for aerosol delivery
|
|
US6485707B2
(en)
|
2001-02-15 |
2002-11-26 |
Aeropharm Technology Incorporated |
Modulated release particles for aerosol delivery
|
|
GB0208742D0
(en)
|
2002-04-17 |
2002-05-29 |
Bradford Particle Design Ltd |
Particulate materials
|
|
US20030129203A1
(en)
*
|
2001-08-27 |
2003-07-10 |
Nautilus Biotech S.A. |
Mutant recombinant adeno-associated viruses
|
|
US20050065118A1
(en)
*
|
2001-10-16 |
2005-03-24 |
Jing Wang |
Organosulfur inhibitors of tyrosine phosphatases
|
|
AUPR868201A0
(en)
*
|
2001-11-05 |
2001-11-29 |
Thorlock International Limited |
Q-factor switching method and apparatus for detecting nuclear quadrupole and nuclear magnetic resonance signals
|
|
WO2003060078A2
(en)
*
|
2001-12-21 |
2003-07-24 |
X-Ceptor Therapeutics, Inc. |
Heterocyclic modulators of nuclear receptors
|
|
EP1465869B1
(en)
|
2001-12-21 |
2013-05-15 |
Exelixis Patent Company LLC |
Modulators of lxr
|
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
|
US20030199594A1
(en)
*
|
2002-04-23 |
2003-10-23 |
Rasik Shah |
Helium propellant composition for use with aerosols
|
|
US20040001801A1
(en)
*
|
2002-05-23 |
2004-01-01 |
Corvas International, Inc. |
Conjugates activated by cell surface proteases and therapeutic uses thereof
|
|
AU2003248747A1
(en)
|
2002-06-27 |
2004-01-19 |
Health Research, Inc. |
Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
|
|
US7053210B2
(en)
|
2002-07-02 |
2006-05-30 |
Health Research, Inc. |
Efficient synthesis of pyropheophorbide a and its derivatives
|
|
US20060020396A1
(en)
*
|
2002-09-09 |
2006-01-26 |
Rene Gantier |
Rational directed protein evolution using two-dimensional rational mutagenesis scanning
|
|
US20050202438A1
(en)
*
|
2002-09-09 |
2005-09-15 |
Rene Gantier |
Rational directed protein evolution using two-dimensional rational mutagenesis scanning
|
|
ES2343518T3
(es)
*
|
2002-09-09 |
2010-08-03 |
Hanall Biopharma Co., Ltd. |
Polipeptidos interferon alfa modificados resistentes a proteasas.
|
|
CA2506415A1
(en)
|
2002-11-19 |
2004-06-03 |
Achillion Pharmaceuticals, Inc. |
Substituted aryl thioureas and releated compounds; inhibitors of viral replication
|
|
JP2006511297A
(ja)
*
|
2002-12-18 |
2006-04-06 |
グラクソ グループ リミテッド |
ベント型マウスピースを有する投薬システム
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
MXPA05009429A
(es)
|
2003-03-05 |
2005-12-12 |
Halozyme Inc |
Glicoproteina hialuronidasa soluble (shasegp), proceso para preparar la misma, usos y composiciones farmaceuticas que la comprenden.
|
|
US7871607B2
(en)
*
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
CN102584813B
(zh)
*
|
2003-05-14 |
2016-07-06 |
Ngc药物公司 |
化合物及其在调节淀粉样蛋白β中的用途
|
|
WO2005000298A2
(en)
*
|
2003-06-03 |
2005-01-06 |
Novartis Ag |
5-membered heterocycle-based p-38 inhibitors
|
|
EP1911754B1
(en)
|
2003-08-13 |
2013-10-09 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
US7420000B2
(en)
|
2003-09-10 |
2008-09-02 |
University Of Southern California |
Amino phosphonate and amino bis-phosphonate derivatives
|
|
US20050148534A1
(en)
*
|
2003-09-22 |
2005-07-07 |
Castellino Angelo J. |
Small molecule compositions and methods for increasing drug efficiency using compositions thereof
|
|
WO2005090370A1
(en)
*
|
2004-02-05 |
2005-09-29 |
The Regents Of The University Of California |
Pharmacologically active agents containing esterified phosphonates and methods for use thereof
|
|
US8519158B2
(en)
|
2004-03-12 |
2013-08-27 |
Ligand Pharmaceuticals Incorporated |
Androgen receptor modulator compounds and methods
|
|
MXPA06013381A
(es)
|
2004-05-20 |
2007-03-01 |
Scripps Research Inst |
Estabilizacion de transtiretina.
|
|
JP2008503490A
(ja)
*
|
2004-06-17 |
2008-02-07 |
センジェント・セラピューティクス・インコーポレイテッド |
チロシンホスファターゼの三置換窒素調節物質
|
|
EP1786421A2
(en)
*
|
2004-07-09 |
2007-05-23 |
Cengent Therapeutics, Inc. |
Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
|
|
WO2006017295A2
(en)
|
2004-07-12 |
2006-02-16 |
Idun Pharmaceuticals, Inc. |
Tetrapeptide analogs
|
|
EP1841749A1
(en)
|
2004-09-02 |
2007-10-10 |
Metabasis Therapeutics, Inc. |
Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
|
|
NZ588432A
(en)
|
2004-09-17 |
2012-03-30 |
Whitehead Biomedical Inst |
Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
|
|
US7998930B2
(en)
|
2004-11-04 |
2011-08-16 |
Hanall Biopharma Co., Ltd. |
Modified growth hormones
|
|
EP1828192B1
(en)
|
2004-12-21 |
2014-12-03 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
CN101189249B
(zh)
|
2005-04-01 |
2013-04-17 |
加利福尼亚大学董事会 |
膦酰基-戊-2-烯-1-基核苷和类似物
|
|
US20060251619A1
(en)
*
|
2005-05-04 |
2006-11-09 |
Gilles Borrelly |
Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
|
|
BRPI0609191B8
(pt)
|
2005-06-17 |
2021-05-25 |
Ligand Pharm Inc |
métodos e compostos moduladores de receptor de androgênio
|
|
WO2007002109A2
(en)
*
|
2005-06-20 |
2007-01-04 |
The Regents Of The University Of California |
Multidentate pyrone-derived chelators for medicinal imaging and chelation
|
|
US20080058282A1
(en)
|
2005-08-30 |
2008-03-06 |
Fallon Joan M |
Use of lactulose in the treatment of autism
|
|
US8492428B2
(en)
*
|
2005-09-20 |
2013-07-23 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
US20070093443A1
(en)
|
2005-10-21 |
2007-04-26 |
Madison Edwin L |
Modified proteases that inhibit complement activation
|
|
US8138361B2
(en)
*
|
2005-12-28 |
2012-03-20 |
The Trustees Of The University Of Pennsylvania |
C-10 carbamates of taxanes
|
|
US8063221B2
(en)
*
|
2006-03-13 |
2011-11-22 |
Kyorin Pharmaceutical Co., Ltd. |
Aminoquinolones as GSK-3 inhibitors
|
|
US20080003202A1
(en)
*
|
2006-03-28 |
2008-01-03 |
Thierry Guyon |
Modified interferon-beta (IFN-beta) polypeptides
|
|
CN101460161A
(zh)
*
|
2006-03-29 |
2009-06-17 |
弗尔德里克斯制药股份有限公司 |
α-突触核蛋白毒性的抑制
|
|
US20070286814A1
(en)
*
|
2006-06-12 |
2007-12-13 |
Medispray Laboratories Pvt. Ltd. |
Stable aerosol pharmaceutical formulations
|
|
EP2423307A1
(en)
|
2006-06-19 |
2012-02-29 |
Catalyst Biosciences, Inc. |
Modified coagulation factor IV polypeptides and use thereof for treatment
|
|
SG170032A1
(en)
|
2006-08-28 |
2011-04-29 |
Kyowa Hakko Kirin Co Ltd |
Antagonistic human light-specific human monoclonal antibodies
|
|
WO2008036379A2
(en)
|
2006-09-21 |
2008-03-27 |
Activx Biosciences, Inc. |
Serine hydrolase inhibitors
|
|
AU2007313961A1
(en)
|
2006-10-09 |
2008-05-08 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
JP2010505961A
(ja)
|
2006-10-09 |
2010-02-25 |
タケダ サン ディエゴ インコーポレイテッド |
キナーゼ阻害剤
|
|
WO2008055236A2
(en)
|
2006-10-31 |
2008-05-08 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors
|
|
US20100137421A1
(en)
*
|
2006-11-08 |
2010-06-03 |
Emmanuel Theodorakis |
Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
|
|
EP2120998B1
(en)
|
2006-11-28 |
2013-08-07 |
HanAll Biopharma Co., Ltd. |
Modified erythropoietin polypeptides and uses thereof for treatment
|
|
WO2009070164A1
(en)
|
2007-11-28 |
2009-06-04 |
University Of Central Florida |
Vigor enhancement via administration of pyrimidine derivatives
|
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
|
AU2007338689A1
(en)
*
|
2006-12-22 |
2008-07-03 |
Encysive Pharmaceuticals, Inc. |
Modulators of C3a receptor and methods of use thereof
|
|
JP5825757B2
(ja)
|
2007-02-11 |
2015-12-02 |
マップ・ファーマシューティカルズ・インコーポレイテッド |
副作用プロファイルを最小限にしながら片頭痛の迅速な緩和を可能にするｄｈｅの治療上の投与方法
|
|
DK2144604T3
(da)
*
|
2007-02-28 |
2011-10-17 |
Conatus Pharmaceuticals Inc |
Fremgangsmåder til behandling af kronisk viral hepatitis C under anvendelse af RO 113-0830
|
|
CA2699151A1
(en)
*
|
2007-09-11 |
2009-03-19 |
Activx Biosciences, Inc. |
Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
|
|
EP2203459B1
(en)
|
2007-09-12 |
2016-03-16 |
Kyorin Pharmaceutical Co., Ltd. |
Spirocyclic aminoquinolones as gsk-3 inhibitors
|
|
CA2699607A1
(en)
|
2007-09-25 |
2009-04-02 |
Takeda Pharmaceutical Company Limited |
Polo-like kinase inhibitors
|
|
US20090264421A1
(en)
*
|
2007-10-05 |
2009-10-22 |
Bible Keith C |
Methods and Compositions for Treating Cancer
|
|
CN101917845A
(zh)
|
2007-11-21 |
2010-12-15 |
法马克西斯制药公司 |
Ssao/vap-1的卤代烯丙胺抑制剂及其用途
|
|
DK2222636T3
(da)
|
2007-12-21 |
2013-06-03 |
Ligand Pharm Inc |
Selektive androgenreceptormodulatorer (SARMS) og anvendelser deraf
|
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
|
US8658163B2
(en)
|
2008-03-13 |
2014-02-25 |
Curemark Llc |
Compositions and use thereof for treating symptoms of preeclampsia
|
|
KR20160052812A
(ko)
|
2008-04-14 |
2016-05-12 |
할로자임, 아이엔씨 |
히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
|
|
US8084025B2
(en)
|
2008-04-18 |
2011-12-27 |
Curemark Llc |
Method for the treatment of the symptoms of drug and alcohol addiction
|
|
JP2011525535A
(ja)
|
2008-06-24 |
2011-09-22 |
武田薬品工業株式会社 |
ＰＩ３Ｋ／ｍＴＯＲ阻害剤
|
|
PL2318035T3
(pl)
|
2008-07-01 |
2019-10-31 |
Curemark Llc |
Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
|
|
CN103205407B
(zh)
|
2008-12-09 |
2016-03-16 |
哈洛齐梅公司 |
延长的可溶性ph20多肽及其用途
|
|
ES2668909T3
(es)
|
2009-01-06 |
2018-05-23 |
Galenagen, Llc |
Composiciones que comprenden proteasa, amilasa y lipasa para su uso en el tratamiento de infecciones por Staphylococcus aureus
|
|
NZ593823A
(en)
|
2009-01-06 |
2013-09-27 |
Curelon Llc |
Compositions and methods for the treatment or the prevention of infections by e. coli
|
|
EP2403523A1
(en)
|
2009-03-06 |
2012-01-11 |
Halozyme, Inc. |
Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
|
|
MX2011009414A
(es)
*
|
2009-03-11 |
2011-10-19 |
Kyorin Seiyaku Kk |
7-cicloalquiloaminoquinolonas como inhibidores de gsk-3.
|
|
JP5730281B2
(ja)
|
2009-03-27 |
2015-06-10 |
武田薬品工業株式会社 |
ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤
|
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
|
JP5715625B2
(ja)
|
2009-07-30 |
2015-05-07 |
武田薬品工業株式会社 |
ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤
|
|
US8404728B2
(en)
|
2009-07-30 |
2013-03-26 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
WO2011041293A1
(en)
|
2009-09-30 |
2011-04-07 |
Takeda Pharmaceutical Company Limited |
Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
|
|
WO2011057214A2
(en)
|
2009-11-09 |
2011-05-12 |
Neurogenetic Pharmaceuticals, Inc. |
Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
|
|
US20110301235A1
(en)
|
2009-12-02 |
2011-12-08 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
|
SG181896A1
(en)
*
|
2009-12-23 |
2012-07-30 |
Map Pharmaceuticals Inc |
Novel ergoline analogs
|
|
EP2521721B1
(en)
|
2009-12-30 |
2014-10-01 |
Shanghai Fochon Pharmaceutical Co. Ltd |
3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
|
|
RS53176B
(en)
|
2010-02-03 |
2014-06-30 |
Takeda Pharmaceutical Company Limited |
KINASE INHIBITORS 1 REGULATING SIGNALS IN APOPTOSIS
|
|
JP6069661B2
(ja)
|
2010-06-24 |
2017-02-01 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用
|
|
MX362974B
(es)
|
2011-04-21 |
2019-02-28 |
Curemark Llc |
Compuestos para el tratamiento de alteraciones neuropsiquiatricas.
|
|
CA2838991A1
(en)
|
2011-06-23 |
2012-12-27 |
Map Pharmaceuticals, Inc. |
Novel fluoroergoline analogs
|
|
WO2013037482A1
(en)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Farnesoid x receptor agonists for cancer treatment and prevention
|
|
CA2859173A1
(en)
|
2011-12-19 |
2013-06-27 |
Map Pharmaceuticals, Inc. |
Novel iso-ergoline derivatives
|
|
SG10201506202RA
(en)
|
2011-12-21 |
2015-09-29 |
Map Pharmaceuticals Inc |
Novel neuromodulatory compounds
|
|
ES2749620T3
(es)
|
2011-12-30 |
2020-03-23 |
Halozyme Inc |
Variantes de polipéptidos de PH20, formulaciones y usos de los mismos
|
|
WO2013134047A2
(en)
|
2012-03-07 |
2013-09-12 |
The Mclean Hospital Corporation |
Aminoquinoline derivatives and uses thereof
|
|
SI2833905T1
(en)
|
2012-04-04 |
2018-08-31 |
Halozyme, Inc. |
Combination therapy with hyaluronidase and tumane-directed taxane
|
|
RS57086B1
(sr)
|
2012-05-02 |
2018-06-29 |
Boehringer Ingelheim Int |
Supstituisani 3-haloalilamin inhibitori ssao i njihova primena
|
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
|
EP2861562B1
(en)
|
2012-06-14 |
2018-05-09 |
Mayo Foundation For Medical Education And Research |
Pyrazole derivatives as inhibitors of stat3
|
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
|
US9074186B2
(en)
|
2012-08-15 |
2015-07-07 |
Boston Medical Center Corporation |
Production of red blood cells and platelets from stem cells
|
|
EP2934143A4
(en)
|
2012-12-21 |
2016-06-15 |
Map Pharmaceuticals Inc |
NOVEL DERIVATIVES OF METHYSERGIDE
|
|
WO2014107745A1
(en)
|
2013-01-07 |
2014-07-10 |
Halozyme, Inc. |
Metal sensitive mutants of matrix metalloproteases and uses thereof
|
|
JP6490597B2
(ja)
|
2013-02-22 |
2019-03-27 |
ユニヴァーシティー オブ サザン カリフォルニア |
眼の疾患および障害を治療するための方法
|
|
EP2968296B1
(en)
|
2013-03-12 |
2020-09-02 |
The Regents of the University of California |
Gamma-secretase modulators
|
|
NZ712479A
(en)
|
2013-03-15 |
2019-01-25 |
Univ Southern California |
Methods, compounds, and compositions for the treatment of angiotensin-related diseases
|
|
NZ714765A
(en)
|
2013-06-06 |
2021-12-24 |
Pf Medicament |
Anti-c10orf54 antibodies and uses thereof
|
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ｐｈ２０玻尿酸酶變異體及其用途
|
|
EP3613418A1
(en)
|
2014-01-17 |
2020-02-26 |
Ligand Pharmaceuticals, Inc. |
Methods and compositions for modulating hormone levels
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
CN106470679A
(zh)
|
2014-05-12 |
2017-03-01 |
科内图斯医药公司 |
用半胱天冬酶抑制剂治疗慢性肝脏疾病并发症
|
|
RS61678B1
(sr)
|
2014-05-28 |
2021-05-31 |
Agenus Inc |
Anti-gitr antitela i postupci za njihovu primenu
|
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
CA2964317C
(en)
|
2014-10-14 |
2021-10-05 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
|
EP3209658A1
(en)
|
2014-10-24 |
2017-08-30 |
Biogen MA Inc. |
Diterpenoid derivatives and methods of use thereof
|
|
WO2016070107A1
(en)
|
2014-10-31 |
2016-05-06 |
The General Hospital Corporation |
Potent gamma-secretase modulators
|
|
KR20240123432A
(ko)
|
2014-12-11 |
2024-08-13 |
피에르 파브르 메디카먼트 |
항-c10orf54 항체들 및 그들의 용도들
|
|
EP3237450B1
(en)
|
2014-12-22 |
2021-03-03 |
The Rockefeller University |
Anti-mertk agonistic antibodies and uses thereof
|
|
US9657020B2
(en)
|
2015-01-20 |
2017-05-23 |
Xoc Pharmaceuticals, Inc. |
Ergoline compounds and uses thereof
|
|
MX2017009406A
(es)
|
2015-01-20 |
2018-01-18 |
Xoc Pharmaceuticals Inc |
Compuestos de tipo isoergolina y usos de estos.
|
|
LT3265123T
(lt)
|
2015-03-03 |
2023-01-25 |
Kymab Limited |
Antikūnai, naudojimas ir būdai
|
|
WO2016176617A2
(en)
|
2015-04-29 |
2016-11-03 |
New York University |
Method for treating high-grade gliomas
|
|
WO2016196237A1
(en)
|
2015-05-29 |
2016-12-08 |
Agenus Inc. |
Anti-ctla-4 antibodies and methods of use thereof
|
|
ES2787073T3
(es)
|
2015-08-17 |
2020-10-14 |
Kura Oncology Inc |
Métodos para tratar pacientes con cáncer con inhibidores de la farnesiltransferasa
|
|
SG10201913276WA
(en)
|
2015-09-01 |
2020-02-27 |
Agenus Inc |
Anti-pd-1 antibodies and methods of use thereof
|
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
|
EP4455145A2
(en)
|
2015-12-02 |
2024-10-30 |
Astraea Therapeutics, LLC |
Piperidinyl nociceptin receptor compounds
|
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
|
AU2016381974A1
(en)
|
2015-12-31 |
2018-07-12 |
Conatus Pharmaceuticals Inc. |
Methods of using caspase inhibitors in treatment of liver disease
|
|
CN108712904B
(zh)
|
2016-01-08 |
2022-08-02 |
细胞基因公司 |
2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的固体形式以及其药物组合物和用途
|
|
JP6956725B2
(ja)
|
2016-01-08 |
2021-11-02 |
セルジーン コーポレイション |
抗増殖化合物、ならびにそれらの薬学的組成物及び使用
|
|
JP6880037B2
(ja)
|
2016-01-08 |
2021-06-02 |
セルジーン コーポレイション |
がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用
|
|
US10960013B2
(en)
|
2016-03-04 |
2021-03-30 |
East Carolina University |
J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
|
|
EP3426352A4
(en)
|
2016-03-08 |
2019-11-13 |
Los Gatos Pharmaceuticals, Inc. |
CAMPTOTHECIN DERIVATIVES AND USES THEREOF
|
|
EP3426301A4
(en)
|
2016-03-08 |
2019-11-06 |
Los Gatos Pharmaceuticals, Inc. |
VERBUNDNANOPARTICLES AND USES THEREOF
|
|
WO2017180794A1
(en)
|
2016-04-13 |
2017-10-19 |
Skyline Antiinfectives, Inc. |
Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
|
|
WO2017184968A1
(en)
|
2016-04-22 |
2017-10-26 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
|
EP4190357A1
(en)
|
2016-05-13 |
2023-06-07 |
Institut Pasteur |
Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
|
|
KR20230091191A
(ko)
|
2016-05-27 |
2023-06-22 |
아게누스 인코포레이티드 |
항-tim-3 항체 및 이의 사용 방법
|
|
MA45602A
(fr)
|
2016-07-08 |
2019-05-15 |
Staten Biotechnology B V |
Anticorps anti-apoc3 et leurs méthodes d'utilisation
|
|
US10919904B2
(en)
|
2016-08-17 |
2021-02-16 |
North Carolina State University |
Northern-southern route to synthesis of bacteriochlorins
|
|
MX2019003683A
(es)
|
2016-10-11 |
2019-08-22 |
Agenus Inc |
Anticuerpos anti gen 3 de activación linfocítica (lag 3 ) y métodos para usarlos.
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
HUE053927T2
(hu)
|
2016-11-03 |
2021-07-28 |
Kura Oncology Inc |
Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra
|
|
JP7045724B2
(ja)
|
2016-11-07 |
2022-04-01 |
ニューラクル サイエンス カンパニー リミテッド |
配列類似性を持つ抗ファミリー１９、メンバーａ５抗体及びその用途
|
|
US10106521B2
(en)
|
2016-11-09 |
2018-10-23 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
|
US10836774B2
(en)
|
2016-11-30 |
2020-11-17 |
North Carolina State University |
Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
|
|
CN118634323A
(zh)
|
2016-12-07 |
2024-09-13 |
艾吉纳斯公司 |
抗体和其使用方法
|
|
EP4289484A3
(en)
|
2016-12-07 |
2024-03-06 |
Agenus Inc. |
Anti-ctla-4 antibodies and methods of use thereof
|
|
ES2892157T3
(es)
|
2017-02-21 |
2022-02-02 |
Kura Oncology Inc |
Métodos de tratamiento del cáncer con inhibidores de farnesil transferasa
|
|
US9956215B1
(en)
|
2017-02-21 |
2018-05-01 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
MX2019012223A
(es)
|
2017-04-13 |
2019-12-09 |
Agenus Inc |
Anticuerpos anti-cd137 y metodos de uso de los mismos.
|
|
KR20190141659A
(ko)
|
2017-04-21 |
2019-12-24 |
스태튼 바이오테크놀로지 비.브이. |
항-apoc3 항체 및 이의 사용 방법
|
|
RS64576B1
(sr)
|
2017-05-01 |
2023-10-31 |
Agenus Inc |
Anti-tigit antitela i postupci njihove primene
|
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
|
WO2018223065A1
(en)
|
2017-06-01 |
2018-12-06 |
Xoc Pharmaceuticals, Inc. |
Ergoline derivatives for use in medicine
|
|
EP3641801A1
(en)
|
2017-06-22 |
2020-04-29 |
Catalyst Biosciences, Inc. |
Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
|
|
CA3067681A1
(en)
|
2017-06-26 |
2019-01-03 |
Institut Pasteur |
Treatments to eliminate hiv reservoirs and reduce viral load
|
|
US11618783B2
(en)
|
2017-06-27 |
2023-04-04 |
Neuracle Science Co., Ltd. |
Anti-FAM19A5 antibodies and uses thereof
|
|
EP3645039A4
(en)
|
2017-06-27 |
2021-05-05 |
Neuracle Science Co., Ltd |
USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS
|
|
KR102511122B1
(ko)
|
2017-06-27 |
2023-03-22 |
주식회사 뉴라클사이언스 |
녹내장의 치료를 위한 항-서열 유사성 19를 가진 패밀리, 멤버 a5 항체의 용도
|
|
US11560425B2
(en)
|
2017-06-27 |
2023-01-24 |
Neuracle Science Co., Ltd. |
Use of anti-FAM19A5 antibodies for treating cancers
|
|
US11168326B2
(en)
|
2017-07-11 |
2021-11-09 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
CA3071854A1
(en)
|
2017-08-07 |
2019-02-14 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2019046556A1
(en)
|
2017-09-01 |
2019-03-07 |
East Carolina University |
COMPOUNDS, COMPOSITIONS, KITS AND METHODS FOR ACTIVATING IMMUNE CELLS AND / OR AN IMMUNE SYSTEM RESPONSE
|
|
EP3692171A4
(en)
|
2017-10-02 |
2021-06-23 |
Neuracle Science Co., Ltd |
USING ANTI-FAMILY WITH SEQUENCE LIKE 19, ELEMENT A5 ANTIBODIES FOR TREATMENT AND DIAGNOSIS OF MENTAL DISORDERS
|
|
CN111315772A
(zh)
|
2017-10-31 |
2020-06-19 |
斯塔顿生物技术有限公司 |
抗apoc3抗体及其使用方法
|
|
WO2019099353A1
(en)
|
2017-11-15 |
2019-05-23 |
California State University Northridge |
Compositions and methods for the treatment and prevention of cancer
|
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
CN112424223A
(zh)
|
2018-04-24 |
2021-02-26 |
纽洛可科学有限公司 |
抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途
|
|
AU2019265888A1
(en)
|
2018-05-10 |
2020-11-26 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
|
US20190351031A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
|
CA3105352A1
(en)
|
2018-06-29 |
2020-01-02 |
Histogen, Inc. |
(s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
|
CA3176812A1
(en)
|
2018-07-11 |
2020-01-16 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
CA3106418A1
(en)
|
2018-07-20 |
2020-01-23 |
Pierre Fabre Medicament |
Receptor for vista
|
|
US11242528B2
(en)
|
2018-08-28 |
2022-02-08 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
WO2020070678A2
(en)
|
2018-10-03 |
2020-04-09 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
|
|
EP3873469A2
(en)
|
2018-11-01 |
2021-09-08 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
EP3880231A1
(en)
|
2018-11-16 |
2021-09-22 |
NeoImmuneTech, Inc. |
Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
|
|
WO2020132071A1
(en)
|
2018-12-19 |
2020-06-25 |
Shy Therapeutics. Llc |
Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
|
|
WO2020128033A1
(en)
|
2018-12-20 |
2020-06-25 |
Institut Pasteur |
Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
|
|
TW202038953A
(zh)
|
2018-12-21 |
2020-11-01 |
美商庫拉腫瘤技術股份有限公司 |
鱗狀細胞癌之治療
|
|
JP2022516725A
(ja)
|
2018-12-28 |
2022-03-02 |
カタリスト・バイオサイエンシーズ・インコーポレイテッド |
改変ウロキナーゼ型プラスミノゲンアクティベータポリペプチドおよび使用方法
|
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
|
TWI839461B
(zh)
|
2019-02-06 |
2024-04-21 |
美商戴斯阿爾法股份有限公司 |
Il-17a調節物及其用途
|
|
CA3130303A1
(en)
|
2019-02-26 |
2020-09-03 |
Rgenix, Inc. |
High-affinity anti-mertk antibodies and uses thereof
|
|
JP2022524951A
(ja)
|
2019-02-27 |
2022-05-11 |
アクティム・セラピューティクス・インコーポレイテッド |
腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌
|
|
US12024709B2
(en)
|
2019-02-27 |
2024-07-02 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
|
WO2020180663A1
(en)
|
2019-03-01 |
2020-09-10 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
BR112021017710A2
(pt)
|
2019-03-07 |
2021-11-16 |
Conatus Pharmaceuticals Inc |
Composto, composição farmacêutica, método de tratamento
|
|
TW202108170A
(zh)
|
2019-03-15 |
2021-03-01 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
|
|
SG11202110472WA
(en)
|
2019-03-29 |
2021-10-28 |
Kura Oncology Inc |
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
|
US20220168296A1
(en)
|
2019-04-01 |
2022-06-02 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2020223583A1
(en)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
|
WO2020236818A1
(en)
|
2019-05-20 |
2020-11-26 |
Nirvana Sciences Inc. |
Narrow emission dyes, compositions comprising same, and methods for making and using same
|
|
KR20220053007A
(ko)
|
2019-08-30 |
2022-04-28 |
아게누스 인코포레이티드 |
항-cd96 항체 및 이의 사용 방법
|
|
MX2022003166A
(es)
|
2019-09-16 |
2022-06-29 |
Dice Alpha Inc |
Moduladores de il-17a y usos de los mismos.
|
|
MX2022005705A
(es)
|
2019-11-12 |
2022-08-16 |
Actym Therapeutics Inc |
Plataformas de suministro bacteriano inmunomoduladoras y su uso para el suministro de productos terapéuticos.
|
|
AU2021207586A1
(en)
|
2020-01-13 |
2022-07-21 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of IL-7 protein and a bispecific antibody
|
|
AU2021217373A1
(en)
|
2020-02-05 |
2022-08-04 |
Neoimmunetech, Inc. |
Method of treating a solid tumor with a combination of an IL-7 protein and CAR-bearing immune cells
|
|
WO2021257828A1
(en)
|
2020-06-18 |
2021-12-23 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
JP2023532312A
(ja)
|
2020-06-30 |
2023-07-27 |
プロセッタ バイオサイエンシズ， インク． |
イソキノリン誘導体、合成の方法及びそれらの使用
|
|
JP2023539454A
(ja)
|
2020-08-12 |
2023-09-14 |
アクティム・セラピューティクス・インコーポレイテッド |
免疫刺激細菌ベースのワクチン、治療薬およびｒｎａデリバリープラットフォーム
|
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
|
US20230398184A1
(en)
|
2020-10-26 |
2023-12-14 |
Neoimmunetech, Inc. |
Methods of inducing stem cell mobilization
|
|
US20240101629A1
(en)
|
2020-11-02 |
2024-03-28 |
Neoimmunetech, Inc. |
Use of interleukin-7 for the treatment of coronavirus
|
|
JP2023549112A
(ja)
|
2020-11-05 |
2023-11-22 |
ネオイミューンテック， インコーポレイテッド |
Ｉｌ－７タンパク質とヌクレオチドワクチンの組み合わせで腫瘍を治療する方法
|
|
WO2022165000A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
|
US20240124483A1
(en)
|
2021-01-27 |
2024-04-18 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
|
CA3211505A1
(en)
|
2021-03-10 |
2022-09-15 |
Lalit Kumar Sharma |
Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
|
|
WO2022226166A1
(en)
|
2021-04-22 |
2022-10-27 |
Protego Biopharma, Inc. |
Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
|
|
EP4347568A1
(en)
|
2021-05-27 |
2024-04-10 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
|
IL309349A
(en)
|
2021-06-14 |
2024-02-01 |
argenx BV |
Antibodies against interleukin 9 and methods of using them
|
|
EP4402124A1
(en)
|
2021-10-22 |
2024-07-24 |
Prosetta Biosciences, Inc. |
Novel host-targeted pan-respiratory antiviral small molecule therapeutics
|
|
CA3237696A1
(en)
|
2021-11-08 |
2023-05-11 |
Progentos Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
|
EP4456907A1
(en)
|
2021-12-30 |
2024-11-06 |
NeoImmuneTech, Inc. |
Method of treating a tumor with a combination of il-7 protein and vegf antagonist
|
|
WO2023129576A2
(en)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Acyclic thiol prodrugs
|
|
US11932665B2
(en)
|
2022-01-03 |
2024-03-19 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
|
US20230331693A1
(en)
|
2022-04-14 |
2023-10-19 |
Bristol-Myers Squibb Company |
Gspt1 compounds and methods of use of the novel compounds
|
|
WO2023198757A1
(en)
|
2022-04-14 |
2023-10-19 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections
|
|
US20240209100A1
(en)
|
2022-10-21 |
2024-06-27 |
Diagonal Therapeutics Inc. |
Heteromeric agonistic antibodies to il-18 receptor
|
|
US20240174695A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Bicyclic Heteroaryl Compounds
|
|
WO2024092037A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing pyridone compounds
|
|
US20240174673A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Pyridine Compounds
|
|
WO2024102722A1
(en)
|
2022-11-07 |
2024-05-16 |
Neoimmunetech, Inc. |
Methods of treating a tumor with an unmethylated mgmt promoter
|
|
WO2024118801A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Linear heteroaryl diamide ire1/xbp1s activators
|
|
WO2024118810A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Cyclic pyrazole diamide ire1/xbp1s activators
|
|
WO2024194686A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
WO2024194685A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
WO2024211796A1
(en)
|
2023-04-07 |
2024-10-10 |
Diagonal Therapeutics Inc. |
Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
|
|
WO2024211807A1
(en)
|
2023-04-07 |
2024-10-10 |
Diagonal Therapeutics Inc. |
Hinge-modified bispecific antibodies
|